“A Twelve week, Multicentre, Double-masked, Parallel Group, Primary Therapy Study and Efficacy of BETAXONTM 0.5% compared to AZOPT® 1% in Pediatric Patients with Glaucoma or Ocular Hypertension” (2004-2005).
“A Twelve week, Multicentre, Double-masked, Parallel Group Primary Therapy Study of the Safety and Efficacy of BETOPTIC®S 0.25% Compared to Timolol Gel Forming Solution 0.25% and 0.5% in Pediatric Patients with Glaucoma or Ocular Hypertension” (2004-2005).
“A multi-center, double-masked study ofthe safety and efficacy of Travoprost APS compared to TRAVATAN® in patients with open- angle glaucoma or ocular hypertension” (2009).
“A phase 3 Prospective, Randomized, Double –Masked, 12week, Parallel group evaluating the efficacy and safety of LATANOPROST and TIMOLOL in pediatric subjects with Glaucoma” (2009).
“ A multicentre, Open label, Active control, Parallel group randomized study to demonstrate Non-inferiority of Brinzolamide 1% ophthalmic suspension compared with Dorzox (Dorzolamide) 2% ophthalmic solution in the treatment ot elevated IOP in patients with Primary Open Angle Glaucoma or Ocular Hypertension” (2009-2010).
“Assessing the Safety and Efficacy of Changing to Travacom (Travoprost/Timolol Fixed Combination), as replacement therapy in patients with uncontrolled intraocular pressure across India” (2010-2011).
“A prospective, Multicentric, randomized controlled, study on long term outcomes of Phacoemulsification with Intra-ocular lens implantation in Pseudo exfoliation syndrome patients” (2010).
“Foveal thickness changes after Phacotrabeculectomy” (2010-2011).
“Effect of newer NSAID (Nepafenac) on foveal thickness changes after phacotrabeculectomy” (2011).
“Prospective Pharmacovigilance cohort study of Ocular Surface Disease (OSD) after use of topical betablockers and prostaglandins” (2011).
“A multicenter, Open-label Study to Evaluate the Safety and Efficacy of Twice-daily 0.01% Bimatoprost / 0.15%Brimonidine / 0.5%Timolol Ophthalmic Solution (Triple Combination) in Patients in India, who Have Glaucoma or Ocular Hypertension With Elevated IOP, and are on Twice-daily 0.2%Brimonidine / 0.5%Timolol Ophthalmic Solution(Dual Combination) Therapy” (2010-2012).
“Efficacy and safety of fixed dose combination of latanoprost 0.005% and timolol 0.5% ophthalmic solution (Sun Pharma Advanced Research Company Ltd) in patients with open angle glaucoma or ocular hypertension: a randomized, open label, parallel group, active controlled study” (2011-2012).
“A Phase III, Randomized, Active Comparator-Controlled, Four-week,Double –Masked Clinical Trial to Compare the Efficacy and Safety ofPreservative-Free MK-2452 (0.0015%) and Preservative- Free Timolol Maleate (0.5%) in Patients with Open –Angle Glaucoma or Ocular Hypertension in India” (2011).
“MOST PROMISING RESEARCH PRESENTATION AWARD” by Glaucoma Society of India- at the XI Annual Meeting of the Glaucoma Society of India, Indore, Madhya Pradesh 2001.
Has set up a Effective and functional model for “REDUCTION OF WAITING TIME IN OUTPATIENT CLINIC” in a crowded eye care system. Accepted and studied by University of Michigan, USA and well received in the London Business School as a model.
“BEST PATIENT CARE PROJECT IMPROVEMENT AWARD” given in American Academy of Ophthalmology on 11th November 2006 in Las Vegas by American Glaucoma Society.
Federation of Indian Chambers of Commerce and Industry (FICCI) Healthcare Excellence Awards 2010 for “EXCELLENCE IN PATIENT EXPERIENCE”.
“WAGH MEMORIAL AWARD” by Pune Ophthalmic Association for outstanding contribution to the field of ophthalmology and community ophthalmology.